glp 1 ilaçları GLP-1 ve Hamilelik İnsülin yerine GLP-1 kullanan diyabet

Our team offers expert guidance on whether BPC-157 is the right choice for your joint pain

company announced the result of its SRUMOUNT study conducted on obese patients with a BMI of 30kg/ or more or those with BMI of 27kg/ or more having one or more weight-related comorbidities

Combined diagnostic value of hsa-miR-592 and hsa-miR-9-3p in plasma for methamphetamine addicts

Not for human use, diagnosis or treatment

In this edition, well explore: How GLP-1 drugs are causing seismic shifts globally How Indias obesity epidemic makes this a massive opportunity The business impact: from pharma to QSRs, fitness to insurance Investment implications across sectors What this means for Indias health future Lets begin